| Zanamivir in the treatment of influenza. | |
| | |
MedLine Citation:
|
PMID: 12740002 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Influenza is a common illness, affecting many people every winter, with a considerable impact on mortality, hospital admissions, healthcare utilisation and sickness absence from work and school. Influenza management is currently focused on annual vaccinations for those in certain risk groups. Risk is determined by age and chronic illness, particularly diabetes, chronic respiratory and cardiac disease, and persons immunocompromised from disease or concomitant therapy. Amantadine (and in some countries, rimantadine is available but has not been widely used, because it is only effective against influenza A infections. The use of amantadines for treatment has been associated with the rapid emergence of resistant viruses capable of transmission, compromising its potential as a prophylactic, as well as a treatment. Side effects are well recognised and are a particular problem in the most vulnerable elderly populations, where dose restriction is necessary and prior knowledge of creatinine clearance desirable. The potential market for a new influenza treatment is large and the potential role of neuraminidase inhibitors in addressing this market has been covered in several review articles [1-4]. This review reports on the introduction of zanamivir (Relenza) to the market with particular reference to experience in the UK. |
| | |
Authors:
|
Douglas M Fleming |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Expert opinion on pharmacotherapy Volume: 4 ISSN: 1465-6566 ISO Abbreviation: Expert Opin Pharmacother Publication Date: 2003 May |
Date Detail:
|
Created Date: 2003-05-12 Completed Date: 2003-07-22 Revised Date: 2008-04-14 |
Medline Journal Info:
|
Nlm Unique ID: 100897346 Medline TA: Expert Opin Pharmacother Country: England |
Other Details:
|
Languages: eng Pagination: 799-805 Citation Subset: IM |
Affiliation:
|
Birmingham Research Unit of the Royal College of General Practitioners, Lordswood House, 54 Lordswood Road, Birmingham B17 9DB, UK. Dfleming@rcgpbhamresunit.nhs.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Animals Antiviral Agents* / pharmacokinetics, pharmacology, therapeutic use Child Clinical Trials as Topic Enzyme Inhibitors* / pharmacokinetics, pharmacology, therapeutic use Guanidines Humans Influenza, Human* / drug therapy, economics, etiology Neuraminidase / antagonists & inhibitors* Pyrans Risk Factors Sialic Acids* / pharmacokinetics, pharmacology, therapeutic use Zanamivir |
| Chemical | |
Reg. No./Substance:
|
0/Antiviral Agents; 0/Enzyme Inhibitors; 0/Guanidines; 0/Pyrans; 0/Sialic Acids; 139110-80-8/Zanamivir; EC 3.2.1.18/Neuraminidase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Safety and efficacy of tenecteplase in acute myocardial infarction.
Next Document: Caspofungin: first approved agent in a new class of antifungals.